By Hartmut Schneider, Dominic Vote and Leon Greenfield ( June 21, 2023, 1:54 PM EDT) -- The Federal Trade Commission's recent complaint in the U.S. District Court for the Northern District of Illinois seeking to enjoin the closing of Amgen Inc.'s proposed $28 billion acquisition of Horizon Therapeutics PLC marks the first time in over 40 years that a U.S. antitrust agency has challenged a transaction based on a conglomerate theory of competitive harm — that is, concerns based on neither direct competition nor a supplier-purchaser relationship between the merging parties....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.